Company intelligence / Profile preview

Compass Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Lead antibody CTX-471 (agonist of CD137) is in Phase 1 for solid tumors with prior failed checkpoint inhibitor therapy. Several preclinical assets in pipeline, including bispecifics targeting innate and adaptive immune checkpoints

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Partnerships

Notable R&D and licensing agreements such as with TRIGR Therapeutics and ABL Bio Inc.

Beyond the preview

Go deeper on Compass Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compass Therapeutics.

Explore the full profile